ALSO NOTED: USC gets $25 million for stem cell research; Analysts betting on Tysabri's return; and much more...

> Two philanthropists have donated $25 million to build a new stem cell research facility at USC. California colleges have been rapidly expanding their stem cell departments in the wake of voters' approval of a $3 billion bond program to support research efforts. Report

> Analysts are betting that the FDA will allow Tysabri back on the market, but with some rigid restrictions on its use. Report

> Par Pharmaceuticals was forced to suspend shipments of generic Flonase after a federal court granted GlaxoSmithKline a temporary restraining order. Report

> France has passed a decree outlining the conditions under which researchers can work with embryonic stem cells. The research community says the decree opens the way for the country to compete in this emerging field. Report

> The FDA is extending its review period for Merck's shingles vaccine. Report

> Canada's ConjuChem has reorganized and received a $6.4 million injection of funds. Release

> Investors have been buying into Zonagen, which is preparing a Phase III trial of a promising therapy for testosterone deficiency. Report

> DUSA Pharmaceuticals reported statistically significant interim results from its 80 patient Phase II clinical study of photodynamic therapy in the treatment of mild to moderate photo-damage (sun induced skin aging) of the face. Release

> Despite complaints, the FDA says it will go ahead with plans to start a program designed to protect pregnant women from the side effects of the acne drug Accutane. Report

> Glenmark Pharmaceuticals has reported the successful finish of a Phase I trial of an experimental diabetes therapy. Report

And Finally... New York state's plan for a flu pandemic: Let the counties decide. Article